PMT PennyMac Mortgage Investment Trust gains 50% Jul 2, 2020

PennyMac Mortgage Investment Trust, a specialty finance company, invests primarily in residential mortgage loans and mortgage-related assets in the United States. The company operates in two segments, Correspondent Production and Investment Activities. The Correspondent Production segment engages in purchasing, pooling, and reselling newly originated prime credit mortgage loans directly or in the form of mortgage-backed securities (MBS). The Investment Activities segment invests in mortgage-related assets, which include distressed mortgage loans, excess servicing spread, real estate acquired in settlement of loans, real estate held for investment, mortgage servicing rights, small balance commercial real estate mortgage loans, and credit risk transfer agreements. PNMAC Capital Management, LLC acts as the manager of PennyMac Mortgage Investment Trust. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. PennyMac Mortgage Investment Trust was founded in 2009 and is based in Westlake Village, California.http://www.priceseries.com/trade/PMT-PennyMac-Mortgage-Investment-Trust-stock-gains-50-percent-a-Trade-Record-by-priceSeries-2020060120200702.html

OOMA Ooma, Inc. gains 23% Jul 7, 2020

Ooma, Inc. provides communications solutions and other connected services to small business, home, and mobile users in the United States and Canadian markets. The company offers Ooma Office, a multi-user communications system for small businesses; and Business Promoter, a service that helps businesses generate new customer leads. Ooma Office consists of an on-premise appliance and an Ooma Linx end-point device, which wirelessly connects regular desktop telephones to the user's high-speed Internet connection. It also provides Ooma Telo, a home communications solution designed to serve as the primary phone line in the home. In addition, the company provides Ooma HD2 handset, a wireless handset that supports various enhanced Ooma features; Ooma Linx, a remote phone jack that allows the user to connect a phone, fax machine, and alarm panel; Ooma Safety Phone, a wireless hands-free speakerphone that can be worn as a pendant; and Ooma Wireless + Bluetooth adapter that adds Wi-Fi and Bluetooth capability to Ooma Telo. It offers its products through direct sales, retailers, and online, as well as through distributors and reseller partnership channels. Ooma, Inc. was incorporated in 2003 and is headquartered in Palo Alto, California.http://www.priceseries.com/trade/OOMA-Ooma-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2020061520200707.html

IPWR Ideal Power Inc. gains 27% Jul 2, 2020

Ideal Power Inc. develops power conversion solutions with a focus on commercial and industrial grid storage, combined solar and storage, and microgrid applications. The company offers 30kW battery converters for the commercial and industrial grid-tied distributed energy storage market; 30kW grid-resilient alternating current (AC) - direct current (DC) power conversion system (PCS); 30kW grid-resilient AC-DC-DC multi-port PCS with two DC ports; 125kW grid-resilient AC-DC PCS; and 125kW grid-resilient AC-DC-DC multi-port PCS for power applications. It also focuses on licensing its proprietary power conversion Power Packet Switching Architecture to original equipment manufacturers. The company sells its products primarily to systems integrators directly, as well as through distribution channel partners in the United States. The company was formerly known as Ideal Power Converters Inc. and changed its name to Ideal Power Inc. in July 2013. Ideal Power Inc. was founded in 2007 and is headquartered in Austin, Texas.http://www.priceseries.com/trade/IPWR-Ideal-Power-Inc-stock-gains-27-percent-a-Trade-Record-by-priceSeries-2020061120200702.html

ATOS Atossa Genetics Inc. gains 64% Jul 2, 2020

Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Afimoxifene Topical Gel for the treatment and prevention of hyperplasia of the breast. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.http://www.priceseries.com/trade/ATOS-Atossa-Genetics-Inc-stock-gains-64-percent-a-Trade-Record-by-priceSeries-2020052820200702.html

TROV TrovaGene, Inc. gains 48% Jul 2, 2020

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA (ctDNA) using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung and colorectal cancers, as well as targeting clinically validated resistance mutations for gene rearrangements, including ALK, RET, and ROS. In addition, it offers laboratory developed tests for pharmaceutical companies and third party laboratories. The company has a license agreement with Nerviano Medical Sciences to develop and commercialize therapeutic candidate PCM-075. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.http://www.priceseries.com/trade/TROV-TrovaGene-Inc-stock-gains-48-percent-a-Trade-Record-by-priceSeries-2020061820200702.html

PMT PennyMac Mortgage Investment Trust gains 50% Jul 2, 2020

PennyMac Mortgage Investment Trust, a specialty finance company, invests primarily in residential mortgage loans and mortgage-related assets in the United States. The company operates in two segments, Correspondent Production and Investment Activities. The Correspondent Production segment engages in purchasing, pooling, and reselling newly originated prime credit mortgage loans directly or in the form of mortgage-backed securities (MBS). The Investment Activities segment invests in mortgage-related assets, which include distressed mortgage loans, excess servicing spread, real estate acquired in settlement of loans, real estate held for investment, mortgage servicing rights, small balance commercial real estate mortgage loans, and credit risk transfer agreements. PNMAC Capital Management, LLC acts as the manager of PennyMac Mortgage Investment Trust. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. PennyMac Mortgage Investment Trust was founded in 2009 and is based in Westlake Village, California.http://www.priceseries.com/trade/PMT-PennyMac-Mortgage-Investment-Trust-stock-gains-50-percent-a-Trade-Record-by-priceSeries-2020060120200702.html

IPWR Ideal Power Inc. gains 27% Jul 2, 2020

Ideal Power Inc. develops power conversion solutions with a focus on commercial and industrial grid storage, combined solar and storage, and microgrid applications. The company offers 30kW battery converters for the commercial and industrial grid-tied distributed energy storage market; 30kW grid-resilient alternating current (AC) - direct current (DC) power conversion system (PCS); 30kW grid-resilient AC-DC-DC multi-port PCS with two DC ports; 125kW grid-resilient AC-DC PCS; and 125kW grid-resilient AC-DC-DC multi-port PCS for power applications. It also focuses on licensing its proprietary power conversion Power Packet Switching Architecture to original equipment manufacturers. The company sells its products primarily to systems integrators directly, as well as through distribution channel partners in the United States. The company was formerly known as Ideal Power Converters Inc. and changed its name to Ideal Power Inc. in July 2013. Ideal Power Inc. was founded in 2007 and is headquartered in Austin, Texas.http://www.priceseries.com/trade/IPWR-Ideal-Power-Inc-stock-gains-27-percent-a-Trade-Record-by-priceSeries-2020061120200702.html

GTHX G1 Therapeutics, Inc. gains 16% Jul 2, 2020

N/Ahttp://www.priceseries.com/trade/GTHX-G1-Therapeutics-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2020061520200702.html

ATOS Atossa Genetics Inc. gains 64% Jul 2, 2020

Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Afimoxifene Topical Gel for the treatment and prevention of hyperplasia of the breast. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.http://www.priceseries.com/trade/ATOS-Atossa-Genetics-Inc-stock-gains-64-percent-a-Trade-Record-by-priceSeries-2020052820200702.html

AFMD Affimed N.V. gains 34% Jul 6, 2020

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Its AFM21 product also binds CD3, directing T-cells to destroy tumor cells that carry EGFRvIII. Affimed N.V. has license agreements with Amphivena Therapeutics, Inc. and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and clinical research collaboration with Merck & Co Inc. It also has a strategic clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate Affimed's TandAb technology in combination with MD Anderson's natural killer cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.http://www.priceseries.com/trade/AFMD-Affimed-NV-stock-gains-34-percent-a-Trade-Record-by-priceSeries-2020061520200706.html